Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 8/20 | 0.79 |
| ▸ | ABL1 | P00519 | 9/20 | 0.76 |
| ▸ | SRC | P12931 | 8/20 | 0.76 |
| ▸ | EGFR | P00533 | 3/20 | 0.72 |
| ▸ | FYN | P06241 | 3/20 | 0.72 |
| ▸ | YES1 | P07947 | 3/20 | 0.72 |
| ▸ | LYN | P07948 | 3/20 | 0.72 |
| ▸ | HCK | P08631 | 3/20 | 0.72 |
| ▸ | KIT | P10721 | 3/20 | 0.72 |
| ▸ | BCR | P11274 | 3/20 | 0.72 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.72 |
| ▸ | EPHB6 | O15197 | 2/20 | 0.72 |
| ▸ | CSF1R | P07333 | 2/20 | 0.72 |
| ▸ | RET | P07949 | 2/20 | 0.72 |
| ▸ | BRAF | P15056 | 2/20 | 0.72 |
| ▸ | EPHA1 | P21709 | 2/20 | 0.72 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.72 |
| ▸ | EPHA3 | P29320 | 2/20 | 0.72 |
| ▸ | EPHA8 | P29322 | 2/20 | 0.72 |
| ▸ | EPHB2 | P29323 | 2/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20045035 | 1.00 | LCK (0.79) | LCKABL1SRCEGFRFYN | |
| SCHEMBL20042583 | 1.00 | LCK (0.79) | LCKABL1SRCEGFRFYN | |
| SCHEMBL20042596 | 0.95 | LCK (0.84) | LCKABL1SRCEGFRFYN | |
| SCHEMBL20042546 | 0.92 | LCK (0.78) | LCKABL1SRCEGFRFYN | |
| SCHEMBL20042550 | 0.92 | LCK (0.78) | LCKABL1SRCEGFRFYN | |
| SCHEMBL20289721 | 0.92 | LCK (0.78) | LCKABL1SRCEGFRFYN | |
| SCHEMBL13626293 | 0.90 | ABL1 (0.89) | LCKABL1SRCEGFRFYN | |
| SCHEMBL20042601 | 0.90 | LCK (0.64) | LCKABL1SRCEGFRFYN | |
| SCHEMBL22092416 | 0.89 | LCK (0.75) | LCKABL1SRCEGFRFYN | |
| SCHEMBL22092304 | 0.89 | LCK (0.75) | LCKABL1SRCEGFRFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236080-B2 | Protein kinase inhibitors | Princeton Drug Discovery, Inc (US) | 2022-02-01 | — | — | US | disclosed |
| CN-108473487-B | Protein kinase inhibitor | 普林斯顿药物研发公司 | 2021-08-03 | — | — | CN | disclosed |
| US-20200123148-A1 | PROTEIN KINASE INHIBITORS | PRINCETON DRUG DISCOVERY INC (US) | 2020-04-23 | — | — | US | disclosed |
| US-10556897-B2 | Protein kinase inhibitors | Princeton Drug Discovery, Inc (US) | 2020-02-11 | — | — | US | disclosed |
| US-10556897-B2 | Protein kinase inhibitors | Princeton Drug Discovery, Inc (US) | 2020-02-11 | — | — | US | disclosed |
| US-10479786-B2 | Protein kinase inhibitors | Princeton Drug Discovery, Inc (US) | 2019-11-19 | — | — | US | disclosed |
| US-20190071437-A1 | PROTEIN KINASE INHIBITORS | PRINCETON DRUG DISCOVERY INC (US) | 2019-03-07 | — | — | US | disclosed |
| US-20190071437-A1 | PROTEIN KINASE INHIBITORS | PRINCETON DRUG DISCOVERY INC (US) | 2019-03-07 | — | — | US | disclosed |
| US-10174018-B2 | Protein kinase inhibitors | PRINCETON DRUG DISCOVERY INC (US) | 2019-01-08 | — | — | US | disclosed |
| WO-2018111893-A1 | PROTEIN KINASE INHIBITORS | PRINCETON DRUG DISCOVERY INC (US) | 2018-06-21 | — | — | WO | disclosed |
| US-20180099960-A1 | PROTEIN KINASE INHIBITORS | PRINCETON DRUG DISCOVERY INC (US) | 2018-04-12 | — | — | US | disclosed |
| US-20180099959-A1 | PROTEIN KINASE INHIBITORS | PRINCETON DRUG DISCOVERY INC (US) | 2018-04-12 | — | — | US | disclosed |
| US-20180099961-A1 | PROTEIN KINASE INHIBITORS | PRINCETON DRUG DISCOVERY INC (US) | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190071437-A1 | PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K2, MAP2K2 | LCK 248/4885ABL1 45/4885SRC 200/4885 |
| US-20180099960-A1 | PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K1 | LCK 313/4885ABL1 93/4885SRC 319/4885 |
| US-20200123148-A1 | PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K2, MAP2K2 | LCK 248/4885ABL1 45/4885SRC 200/4885 |
| US-10556897-B2 | Protein kinase inhibitors | MAP3K20, MAP3K2, MAP2K2 | LCK 248/4885ABL1 45/4885SRC 200/4885 |
| US-20180099961-A1 | PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K1 | LCK 313/4885ABL1 93/4885SRC 319/4885 |
| US-10479786-B2 | Protein kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | LCK 313/4885ABL1 93/4885SRC 319/4885 |
| US-20180099959-A1 | PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K1 | LCK 313/4885ABL1 93/4885SRC 319/4885 |
| US-10174018-B2 | Protein kinase inhibitors | MAP3K20, MAP3K2, MAP2K2 | LCK 248/4885ABL1 45/4885SRC 200/4885 |
| US-11236080-B2 | Protein kinase inhibitors | MAP3K20, MAP3K2, MAP2K2 | LCK 248/4885ABL1 45/4885SRC 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.